Daratumumab was the first fully human anti-CD38 monoclonal antibody (mAb) to be tested in clinical trials,1 demonstrating efficacy as a single agent in patients with relapsed/refractory multi- ple myeloma (RRMM). Daratumumab exerts direct antitumor and indirect immunomodulatory effects by targeting CD38, a cell surface receptor highly expressed on neoplastic plasma cells.

Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study / Attardi, Enrico; Pilerci, Sofia; Attucci, Irene; Buzzichelli, Alessandra; Messeri, Maria; Staderini, Michela; Vannucchi, Alessandro M; Antonioli, Elisabetta. - In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - ISSN 2152-2650. - ELETTRONICO. - 21:(2021), pp. e850-e852. [10.1016/j.clml.2021.06.018]

Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study

Attardi, Enrico;Pilerci, Sofia;Attucci, Irene;Buzzichelli, Alessandra;Messeri, Maria;Staderini, Michela;Vannucchi, Alessandro M;Antonioli, Elisabetta
2021

Abstract

Daratumumab was the first fully human anti-CD38 monoclonal antibody (mAb) to be tested in clinical trials,1 demonstrating efficacy as a single agent in patients with relapsed/refractory multi- ple myeloma (RRMM). Daratumumab exerts direct antitumor and indirect immunomodulatory effects by targeting CD38, a cell surface receptor highly expressed on neoplastic plasma cells.
2021
21
e850
e852
Attardi, Enrico; Pilerci, Sofia; Attucci, Irene; Buzzichelli, Alessandra; Messeri, Maria; Staderini, Michela; Vannucchi, Alessandro M; Antonioli, Elisabetta
File in questo prodotto:
File Dimensione Formato  
S2152265021002470.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: DRM non definito
Dimensione 132.03 kB
Formato Adobe PDF
132.03 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1257167
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact